A Phase I Open-Label Dose Escalation Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2007
At a glance
- Drugs Siplizumab (Primary)
- Indications Cutaneous T cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 13 Jun 2007 Status changed from recruiting to discontinued.
- 01 Feb 2007 The expected number of patients changed from 68 to 80 in February 2007.